A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.
The European Union has approved the marketing of the new treatment Opdualag for the treatment of melanoma patients. New data demonstrates that the treatment resulted in the complete disappearance of tumours in 16.3% of patients, a significant reduction in tumours in 26.8% and stable disease without further progression in 18.2% of patients, giving an efficiency rate of 61.3%.
